LTR Pharma Limited (AU:LTP) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
LTR Pharma Limited reports significant progress in the development of SPONTAN, a promising new nasal spray treatment for Erectile Dysfunction (ED), with the completion of a pivotal clinical study and the production of the first commercial batch. The company, well-funded with a $5.28 million cash balance, is on track to meet its milestones and is gearing up for a potential market shake-up in the global ED treatment landscape. With the study’s results anticipated by mid-2024, LTR Pharma is preparing for regulatory submissions and commercial launch.
For further insights into AU:LTP stock, check out TipRanks’ Stock Analysis page.